Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.
March 26, 2023
Hence, this important publication presents a great opportunity for NucleoCapture colums to be used for diagnostic purposes, where cell-free DNA fragments can be progressively removed from a patient’s blood using histone conjugated polymer beads and used to monitor post-treatment complications.
September 30, 2021
Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.
Santersus AG is proud to be recognized as a top innovator and to be granted a presentation slot at the transCampus Partnership 10 year Anniversary Event in London on February 13, 2023.
Minister President of Saxony, Michael Kretschmer honored the transCampus partnership and its success during his keynote speech at the anniversary celebration.